RetaCagri
Combination of Retatrutide and Cagrilintide targeting four metabolic receptors
Clinical Research Score: 3/5 — Its components (retatrutide and cagrilintide) have individual trial data, but this specific combination has no dedicated clinical trials.
Categories: Weight Loss / Metabolic
What is RetaCagri?
RetaCagri is the theoretical maximum of combination weight loss therapy — four distinct receptor pathways targeted simultaneously. It pairs retatrutide (which already activates three pathways: GLP-1, GIP, and glucagon) with cagrilintide (which adds a fourth: amylin). No other combination covers more metabolic ground.
Early user reports suggest the most powerful appetite suppression seen with any peptide protocol. Hunger essentially disappears. Fat loss is rapid and significant. Metabolic markers improve across the board — blood sugar, liver fat, cholesterol, and inflammatory markers all trend in the right direction.
This is advanced combination therapy — it's not where most people start, but it's where those seeking maximum metabolic transformation eventually arrive. The four-receptor approach means that appetite is suppressed from every available angle while energy expenditure is simultaneously increased. It's the most comprehensive metabolic intervention currently available in the peptide space.
How RetaCagri works
RetaCagri provides the broadest metabolic receptor coverage available: retatrutide activates GLP-1R (appetite suppression), GIPR (insulin sensitization), and GCGR (increased energy expenditure and liver fat burning), while cagrilintide adds AMYR activation (additional satiety, gastric slowing, and glucagon suppression). Four receptors, four complementary pathways, all working simultaneously to reduce food intake, improve metabolic function, and increase energy expenditure.
Scientific overview
RetaCagri is an emerging combination protocol pairing retatrutide (triple GLP-1/GIP/glucagon agonist) with cagrilintide (long-acting amylin analog). This combination targets four distinct receptor pathways — GLP-1, GIP, glucagon, and amylin — providing the broadest metabolic coverage of any weight management approach. The rationale is to achieve maximum appetite suppression and metabolic enhancement through complementary and non-overlapping mechanisms.
Dosing
- Starting dose: 0.5 mg reta / 0.25 mg cagri per week
- Common dosage range: Titrated per individual response
- Administration: Subcutaneous
- Half-life: ~6-7 days (both components)
- Frequency: Once weekly